Navigation Links
Heat shock proteins are co-opted for cancer
Date:9/20/2007

CAMBRIDGE, Mass. (Sept. 20, 2007) A Jekyll-Hyde mechanism that both protects healthy cells and enables cancer cells could be the basis for new cancer-fighting drugs.

Scientists in the laboratory of Whitehead Member Susan Lindquist have discovered that a certain transcription factora protein that binds to specific areas of the genome and acts to switch genes on and offknown to aid in handling stresses also facilitates the survival of cancer cells.

According to the study, which appears online in Cell on Sept. 20, this transcription factor may be the basis for powerful new ways to fight cancer.

The transcription factor is the master regulator of cells protective heat-shock responsea complex and multifaceted defense system that kicks in when an organism is exposed to increased temperature, infection, toxins or other stresses. The heat-shock response is thought to have existed for more than a billion years and is found in organisms from bacteria to fruit flies to humans.

Heat-shock transcription factors turn on genes for helpful chaperone proteins that help keep proteins from going bad. If proteins form unhealthy clumps, heat-shock proteins (HSPs) pull them apart. If proteins misfold, HSPs help them refold. If the errant proteins are too far gone, HSPs ship them off to be destroyed.

Postdoctoral associate Chengkai Dai and his colleagues looked at the role of heat-shock factor 1 (HSF1), the master regulator of the heat-shock response, in enabling normal cells to turn into cancer cells.

This work provides the first direct evidence of an important role for HSF1 in helping cells to undergo a malignant transformation, says co-author Luke Whitesell, a research scientist in the Lindquist lab.

While the transcription factor does not itself cause the transformation of a normal cell into a cancer cell, it orchestrates a network of core functions in the cancer cells that govern their proliferation, survival, protein synthesis and metabolism.

In mice, an HSF1 deficiency drastically limited tumor formation induced by either a chemical carcinogen or a cancer-causing genetic mutation.

Using cells from a variety of human tumors, Dai showed that depriving the cancer cells of HSF1 strongly suppressed their ability to grow and survive. We propose that HSF1 could provide a uniquely effective target for the discovery of broadly active anticancer agents, says Lindquist.

Its increasingly apparent, Whitesell comments, that many biological mechanisms can play dual rolessometimes beneficial, sometimes not.

It makes perfect sense to us that HSF1 plays this dual role, Dai says. It has been shown that HSF1 is involved in protecting against neurodegeneration, in which brain cells die slowly over time. In cancer, the opposite is true: cancer cells dont die. Ironically, cancer cells hijack and exploit this evolutionarily conserved self-protective function of HSF1.

In fact, he says, cancer cells appear much more sensitive than normal cells to the loss of HSF1 function.

It will be interesting to see how the insights gained from studies such as this one can be applied to develop useful therapeutics, Whitesell says. The next step is to look for existing compounds that induce or inhibit the heat-shock response in cells. The challenge will be to manipulate the target for therapeutic advantage without tipping the scales too much or in the wrong places.


'/>"/>

Contact: Eric Bender
bender@wi.mit.edu
617-258-9183
Whitehead Institute for Biomedical Research
Source:Eurekalert

Related medicine news :

1. Shock it to Heal!!
2. Aprotinin in the treatment of hemorrhagic shock trauma patients
3. New Implantable Cardioverter Defibrillators to avoid unnecessary shocks
4. Shocked out of drugs?
5. Shock Wave Therapy Increase The Risk Of Diabetes
6. Health Experts Shocked As 11-year-old Girl To Be UKs Youngest Mother
7. Cardiogenic Shock is the Leading Cause of Death for Heart Attack Patients
8. Radioprotective effect of Heat Shock Proteins
9. New Study Finds On/Off Switch for Septic Shock
10. Are call centers turning a deaf ear to potential acoustic shocks?
11. Hong Kong - HIV Test Shock Sparks Warning
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... Nevada (PRWEB) , ... June 24, 2016 , ... ... Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations ... in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 23, 2016  In a startling report released today, National ... by lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... of how states are tackling the worst drug crisis in recorded ... – Kentucky , New Mexico ... . Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
Breaking Medicine Technology: